
The British Society for Nanomedicine Annual Meeting 2026 showcased recent advances across the breadth of the nanomedicine and advanced therapies sectors. Key themes included the development of innovative materials and therapeutic approaches, alongside the importance of understanding nano–bio interactions and adopting robust methods for nanoparticle characterization. The meeting concluded with a panel discussion entitled Accelerating Nanomedicine Translation in the UK: What Needs to Change?, which brought together many of the challenges discussed throughout the conference. While innovative discovery remains central to the advancement of nanomedicines, the meeting focused on the interdisciplinary challenges associated with translation to clinical application.
Nanozymes integrate the tunable microstructure of nanomaterials with the catalytic activity of natural redox enzymes, positioning them as frontier candidates in catalytic medicine. Their catalytic stability, multi-enzyme synergy and low-cost scalable synthesis are offset by nano-specific risks--accumulation, free metal leakage, protein-corona-driven immune disturbance and complement activation--that preclude direct application of conventional drug-evaluation guidelines. In this narrative review, evidence was retrieved from [PubMed, Web of Science, Scopus, CNKI; January 2007-June 2026]. This review surveys the microstructure-activity relationships, standardized preparation and disease-intervention mechanisms of five representative nanozymes (Fe3O4, CeO2, noble-metal, single-atom carbon-based and metal-organic framework (MOF)-based). Benchmarking against the International Council for Harmonization (ICH) guideline suite and National Medical Products Administration (NMPA) nanomedicine-specific technical guidelines, it proposes an integrated non-clinical evaluation framework spanning quality control, absorption, distribution, metabolism and excretion (ADME), multi-level toxicology and efficacy stratification, and outlines translational bridging through backbone cross-comparison and the ethylenediaminetetraacetic acid (EDTA)-intercalated layered double hydroxide (LDH) paradigm. No nanozyme has yet been approved as a drug; translation hinges on quantifying structure-activity relationships, harmonizing nano-specific evaluation standards and generating early human data. Precision material design, standardized catalytic-activity assays and exploratory clinical studies are the near-term priorities.